These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 20644113)

  • 21. The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys.
    Schwoebel F; van Eijk LT; Zboralski D; Sell S; Buchner K; Maasch C; Purschke WG; Humphrey M; Zöllner S; Eulberg D; Morich F; Pickkers P; Klussmann S
    Blood; 2013 Mar; 121(12):2311-5. PubMed ID: 23349391
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Involvement of hepcidin in the anemia of multiple myeloma.
    Sharma S; Nemeth E; Chen YH; Goodnough J; Huston A; Roodman GD; Ganz T; Lichtenstein A
    Clin Cancer Res; 2008 Jun; 14(11):3262-7. PubMed ID: 18519751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Immunotherapy using IL-6 receptor as the target].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):399-404. PubMed ID: 18974624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of anti-interleukin-6 receptor monoclonal blockade in a renal transplant patient with Castleman disease: early post-transplant outcome.
    Matsunami M; Ubara Y; Sumida K; Oshima Y; Oguro M; Kinoshita K; Tanaka K; Nakamura Y; Kinowaki K; Ohashi K; Fujii T; Igawa T; Sato Y; Ishii Y
    BMC Nephrol; 2018 Oct; 19(1):263. PubMed ID: 30314457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation.
    Roy CN; Mak HH; Akpan I; Losyev G; Zurakowski D; Andrews NC
    Blood; 2007 May; 109(9):4038-44. PubMed ID: 17218383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained remission of multicentric Castleman disease in children treated with tocilizumab, an anti-interleukin-6 receptor antibody.
    Galeotti C; Boucheron A; Guillaume S; Koné-Paut I
    Mol Cancer Ther; 2012 Aug; 11(8):1623-6. PubMed ID: 22638145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases.
    Ohsugi Y
    Biol Pharm Bull; 2007 Nov; 30(11):2001-6. PubMed ID: 17978466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody.
    Kanda J; Kawabata H; Yamaji Y; Ichinohe T; Ishikawa T; Tamura T; Furukawa Y; Kimura T; Kita T; Uchiyama T
    Int J Hematol; 2007 Apr; 85(3):207-11. PubMed ID: 17483056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Anti-interleukin-6 receptor antibody therapy--from bedside to bench].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2006 Oct; 29(5):289-94. PubMed ID: 17075187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia.
    Sasu BJ; Cooke KS; Arvedson TL; Plewa C; Ellison AR; Sheng J; Winters A; Juan T; Li H; Begley CG; Molineux G
    Blood; 2010 Apr; 115(17):3616-24. PubMed ID: 20053755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
    Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K
    Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anemia of inflammation: the cytokine-hepcidin link.
    Andrews NC
    J Clin Invest; 2004 May; 113(9):1251-3. PubMed ID: 15124013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacological and clinical profile of anti-human IL-6 receptor antibody (tocilizumab, ACTEMRA), a novel therapeutic drug for Castleman's disease].
    Ohsugi Y; Tsuchimoto N
    Nihon Yakurigaku Zasshi; 2005 Dec; 126(6):419-25. PubMed ID: 16462093
    [No Abstract]   [Full Text] [Related]  

  • 34. IL-22 regulates iron availability in vivo through the induction of hepcidin.
    Smith CL; Arvedson TL; Cooke KS; Dickmann LJ; Forte C; Li H; Merriam KL; Perry VK; Tran L; Rottman JB; Maxwell JR
    J Immunol; 2013 Aug; 191(4):1845-55. PubMed ID: 23836059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.
    Nishimoto N; Kanakura Y; Aozasa K; Johkoh T; Nakamura M; Nakano S; Nakano N; Ikeda Y; Sasaki T; Nishioka K; Hara M; Taguchi H; Kimura Y; Kato Y; Asaoku H; Kumagai S; Kodama F; Nakahara H; Hagihara K; Yoshizaki K; Kishimoto T
    Blood; 2005 Oct; 106(8):2627-32. PubMed ID: 15998837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulation of hepcidin transcription by interleukin-1 and interleukin-6.
    Lee P; Peng H; Gelbart T; Wang L; Beutler E
    Proc Natl Acad Sci U S A; 2005 Feb; 102(6):1906-10. PubMed ID: 15684062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin.
    Nemeth E; Rivera S; Gabayan V; Keller C; Taudorf S; Pedersen BK; Ganz T
    J Clin Invest; 2004 May; 113(9):1271-6. PubMed ID: 15124018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron-deficiency anemia in Castleman disease: implication of the interleukin 6/hepcidin pathway.
    Arlet JB; Hermine O; Darnige L; Ostland V; Westerman M; Badoual C; Pouchot J; Capron L
    Pediatrics; 2010 Dec; 126(6):e1608-12. PubMed ID: 21041280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Iron sequestration and anemia of inflammation.
    Ganz T; Nemeth E
    Semin Hematol; 2009 Oct; 46(4):387-93. PubMed ID: 19786207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling.
    Besson-Fournier C; Latour C; Kautz L; Bertrand J; Ganz T; Roth MP; Coppin H
    Blood; 2012 Jul; 120(2):431-9. PubMed ID: 22611157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.